Amylyx Drug Hits Main Goal in Trial for Post-bariatric Hypoglycemia

Amylyx Pharmaceuticals said Tuesday that its experimental drug met the main goal of a pivotal trial, significantly helping patients who experience sudden drops in blood sugar after bariatric surgery. The company announced the positive readout in a statement, marking a key milestone for the drug candidate.